Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Long-term continuation rate good for Alza's overactive bladder therapy

Aug. 30, 1999

Long-term tolterodine reduces incontinence, is well tolerated

Aug. 30, 1999

Ferring's antidiuretic agent F-992 evaluated in healthy volunteers

Aug. 26, 1999

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Aug. 23, 1999

Sanofi-Synthelabo submits MAA for Ditropan XL in the U.K.

Aug. 16, 1999

Leading BPH treatment to be copromoted by Abbott and Boehringer Ingelheim

Aug. 16, 1999

NexMed reports results from multiple-use study of topical alprostadil cream

Aug. 16, 1999

NIH initiates interstitial cystitis trial

Aug. 16, 1999

Phase II testing of Alexion's C5 complement inhibitor also begins in renal diseases

Aug. 12, 1999

FDA puts hold on clinical study of Vasomax

Aug. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...